Alveus Therapeutics
Alveus Therapeutics is a startup headquartered in Philadelphia, United States, founded in 2023. It has raised at least $56.9m in outside funding, according to its filings with the US Securities and Exchange Commission (Form D), which puts it at the growth stage.
Part of the 311 Institute Global Startups Directory (311institute.com). Last updated .
Funding
Alveus Therapeutics has raised at least $56.9m in outside funding, according to its Form D filings with the US Securities and Exchange Commission. Form D figures are a minimum: not every round is filed.
R&D ecosystem
Alveus Therapeutics sits inside the Philadelphia region R&D ecosystem in the Global R&D Labs Directory.
Other startups in Philadelphia
- BlueWhale Bio
- Daymark Health
- FORE US Bio
- Interius BioTherapeutics
- Metabolics Pharma
- OnCall Health
- Peptaris
- QualiaOS
- Ritten
- Tolerance Bio
- Twenty30 Health
Related
- Innovation profile of Philadelphia
- United States: economy and key statistics
- Global Investors Directory
- All 311 Indexes
Questions and answers
What does Alveus Therapeutics do?
Alveus Therapeutics is classed in pharmaceuticals in its filings with the US Securities and Exchange Commission.
How much has Alveus Therapeutics raised?
At least $56.9m, according to its Form D filings with the US Securities and Exchange Commission.
Where is Alveus Therapeutics based?
Alveus Therapeutics is headquartered in Philadelphia, United States.
When was Alveus Therapeutics founded?
Alveus Therapeutics was founded in 2023.
Source record: SEC EDGAR (Form D filings).
© 311 Institute 2026. Facts from the official sources linked on this page. The selection, classification and links are the proprietary work of the 311 Institute, protected by copyright and database rights.